Article Text

Download PDFPDF
Ponder of concern and long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil
  1. Ankur Jindal1,
  2. Ashish Vyas2,
  3. Garima Dubey3
  1. 1Hepatology, Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
  2. 2Microbiology, All India Institute of Medical Science—Bhopal, Bhopal, Madhya Pradesh, India
  3. 3Department of Microbiology, All India Institute of Medical Science—Bhopal, Bhopal, Madhya Pradesh, India
  1. Correspondence to Dr Ankur Jindal, Hepatology, Institute of Liver and Biliary Sciences, New Delhi 110070, India; ankur.jindal3{at}gmail.com

Statistics from Altmetric.com

We read with interest the important article by Pan CQ and colleagues, wherein they demonstrated the long-term safety of infants whose mothers were treated with tenofovir disoproxil fumarate (TDF) during pregnancy.1 However, we feel that the findings are not universally applicable and may not have an influence on clinical practice.

In this study, infants were exposed to TDF for a short median duration of 8.2 weeks. It is known that the adverse effects of TDF on bone mineral density …

View Full Text

Footnotes

  • Contributors AJ and AKV: drafter and edited the file. GD: literature review.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.